RALPH E WOOD, DO
Marriage and Family Therapists at Lafayette Ave, Moundsville, WV
License number
West Virginia 839
Category
Osteopathic Medicine
Type
Family Medicine
Address
Address
1307 Lafayette Ave, Moundsville, WV 26041
Phone
(304) 845-2500
(304) 845-2624 (Fax)
(304) 845-2624 (Fax)
Organization information
See more information about RALPH E WOOD at bizstanding.comRALPH E. WOOD, D.O. PROFESSIONAL CORPORATION
1001 3 St, Moundsville, WV 26041
Status:
Inactive
Inactive reason:
Dissolution by Court Order
Registration:
Dec 1, 1985
Inactive since:
Dec 16, 1987
Business type:
Corporation
Incorporator:
Ralph E. Wood, D.o (Incorporator), 1001 3 St, Moundsville, WV 26041
Professional information
Method Of Treating Peripheral Vascular Diseases, Peripheral Neuropathies, And Autonomic Neuropathies
US Patent:
2004017, Sep 9, 2004
Filed:
Mar 10, 2004
Appl. No.:
10/798135
Inventors:
Ralph Wood - Moundsville WV, US
Assignee:
Pfizer Inc
International Classification:
A61K031/519
US Classification:
514/252160, 514/262100
Abstract:
A method of treating a patient suffering from peripheral vascular disease, peripheral neuropathies, or autonomic neuropathies by administering a cGMP PDE5 inhibitor such as sildenafil. The method is particularly applicable to patients suffering from diabetic foot ulcers, Raynaud's Phenomenon, CREST Syndrome, erythromatosis, rheumatoid diseases, diabetic retinopathies and onychiomycosis. According to the present invention, a cGMP PDE5 inhibitor may be administered as a prophylactic to patients predisposed to develop a peripheral vascular disease, peripheral neuropathy or autonomic neuropathy.
Treatment Of Diabetic Ulcers
US Patent:
2003017, Sep 18, 2003
Filed:
Mar 7, 2003
Appl. No.:
10/169921
Inventors:
Ralph Wood - Moundsville WV, US
Michael Davies - Manchester, GB
Richard Siegel - New York NY, US
Michael Davies - Manchester, GB
Richard Siegel - New York NY, US
International Classification:
A61K031/519
US Classification:
514/252160
Abstract:
This invention relates to the use of cyclic guanosine 3′, 5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of diabetic ulcers, particularly diabetic foot ulcers.